Gail Roboz, MD

Articles

Dr. Roboz on the Importance of Genomic Analysis in AML

August 2nd 2021

Gail J. Roboz, MD, discusses the importance of utilizing genomic analysis to help guide treatment decisions in patients with acute myeloid leukemia.

Dr. Roboz on Recent Therapeutic Developments in AML

July 27th 2021

Gail J. Roboz, MD, discusses recent therapeutics developments in the treatment of patients with acute myeloid leukemia.

Dr. Roboz on the QuANTUM-R Trial in AML

June 16th 2019

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.

Dr. Roboz on Evolving Paradigms in AML Treatment

August 25th 2017

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses evolving paradigms in treatment of patients with acute myeloid leukemia (AML).

Dr. Roboz on Advancements on the Horizon in AML

August 18th 2017

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses advancements emerging on the horizon in acute myeloid leukemia (AML).

Dr. Roboz on Challenges With CAR T-cell Therapy in ALL

August 4th 2017

Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).